Georgia's Online Cancer Information Center

Find A Doctor

Howard A Zaren MD, FACS
Howard A Zaren MD, FACS
Nancy N. and J.C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
www.sjchs.org

Howard A Zaren MD, FACS

Specialty
Surgery and Surgical Oncology / Board Certified
Distinctions
GCC Distinguished Cancer Scholar
Trial Cancers
Appendix Cancer, Bladder Cancer, Bone and Soft Tissue (including Sarcoma), Brain Cancer , Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Endometrial Cancer, Eye Cancer, Gynecologic Cancers, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Primaries, Non-Hodgkin Lymphoma, Prostate Cancer , Quality of Life, Skin Cancer (Non-Melanoma), Solid Tumor
Affiliations
St. Joseph's/Candler
Education

Medical School: University of Manitoba Medical School, Manitoba, Canada

Internship: Pennsylvania Hospital, Philadelphia, Pennsylvania

Residency: Pennsylvania Hospital, Philadelphia, Pennsylvania

Fellowship: University of Texas System Cancer Center, Houston, Texas

Active Clinical Trial Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Appendix Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
Cancer Type: Bladder Cancer

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Bone and Soft Tissue (including Sarcoma)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Brain Cancer

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Breast Cancer

Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
Cancer Type: Breast Cancer

A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
Cancer Type: Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Cancer Type: Breast Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Cancer Type: Cervical Cancer

A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
Cancer Type: Cervical Cancer

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Colon/Rectal Cancer

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced / Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
Cancer Type: Colon/Rectal Cancer

A Four Arm Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combination of Cediranib / Olaparib and the Combination of Olaparib / Wee1 Inhibitor AZD1775 in Women with Recurrent, Persistent or Metastatic Endometrial Cancer (EEC)
Cancer Type: Endometrial Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Cancer Type: Gynecologic Cancers

Assessing the Impact of a Simplified Patient Care Strategy to Decrease Early Deaths In Acute Promyelocytic Leukemia (APL) By Maintaining A Database
Cancer Type: Leukemia

INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
Cancer Type: Lung Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Lymphoma

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Cancer Type: Lymphoma

A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
Cancer Type: Lymphoma

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Melanoma

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Cancer Type: Melanoma

A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Cancer Type: Melanoma

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Multiple Primaries

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Non-Hodgkin Lymphoma

A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
Cancer Type: Prostate Cancer

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Cancer Type: Skin Cancer (Non-Melanoma)

A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Cancer Type: Skin Cancer (Non-Melanoma)

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Solid Tumor

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type: Unknown Primary

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Unknown Primary

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Unknown Primary

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Unknown Primary

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Unknown Primary
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a state-supported nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education to improve cancer care for Georgians in rural, urban, and suburban communities across the state.